Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
Suntory Oceania's CEO Darren Fullerton to retire in 2025
Today, Suntory Oceania has announced that Darren Fullerton, CEO of Suntory Beverage & Food...
Grant Thornton's Dealtracker report for Ag, F&B sector
Grant Thornton's latest analysis report on agribusiness, food & beverage reveals mergers...
NZ Government plans to cut red tape for food exporters
The New Zealand Government is planning to make it easier for food exporters to take advantage of...
